Meeting NewsVideo

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology.

The institute, an initiative of the Association of Community Cancer Centers, is designed to allow experts from academic facilities share their expertise in cancer immunotherapies directly with community providers.

Naidoo, assistant professor of oncology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and Bloomberg Kimmel Institute for Cancer Immunotherapy, participates in the institute’s visiting expert program.

Through this effort, medical oncologists, nursing specialists and pharmacists with experience delivering and managing immuno-oncology agents share their expertise with community providers in a 1-day program.

Topics include delivery of agents, safety, immune-related toxicity and reimbursement.

“We look forward to [the institute] being something that community providers can engage with to answer any relevant questions in immuno-oncology,” Naidoo told HemOnc Today. – by Mark Leiser

Disclosure: Naidoo reports research funding from AstraZeneca and Merck; consultant and advisory fees from AstraZeneca, Bristol-Myers Squibb and Takeda; and honoraria from Bristol-Myers Squibb.

CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology.

The institute, an initiative of the Association of Community Cancer Centers, is designed to allow experts from academic facilities share their expertise in cancer immunotherapies directly with community providers.

Naidoo, assistant professor of oncology at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and Bloomberg Kimmel Institute for Cancer Immunotherapy, participates in the institute’s visiting expert program.

Through this effort, medical oncologists, nursing specialists and pharmacists with experience delivering and managing immuno-oncology agents share their expertise with community providers in a 1-day program.

Topics include delivery of agents, safety, immune-related toxicity and reimbursement.

“We look forward to [the institute] being something that community providers can engage with to answer any relevant questions in immuno-oncology,” Naidoo told HemOnc Today. – by Mark Leiser

Disclosure: Naidoo reports research funding from AstraZeneca and Merck; consultant and advisory fees from AstraZeneca, Bristol-Myers Squibb and Takeda; and honoraria from Bristol-Myers Squibb.

    See more from ASCO Annual Meeting